India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

February 1, 2025 India's Biocon plans IPO for biosimilars business by March 2026 Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for ...